TW201900203A - Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively - Google Patents

Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively Download PDF

Info

Publication number
TW201900203A
TW201900203A TW106116586A TW106116586A TW201900203A TW 201900203 A TW201900203 A TW 201900203A TW 106116586 A TW106116586 A TW 106116586A TW 106116586 A TW106116586 A TW 106116586A TW 201900203 A TW201900203 A TW 201900203A
Authority
TW
Taiwan
Prior art keywords
kidney
aloe
powder
group
adenine
Prior art date
Application number
TW106116586A
Other languages
Chinese (zh)
Inventor
陳璟賢
Original Assignee
陳璟賢
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陳璟賢 filed Critical 陳璟賢
Priority to TW106116586A priority Critical patent/TW201900203A/en
Publication of TW201900203A publication Critical patent/TW201900203A/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides an aloe/pig kidney composite composition containing the aloe dried powder and the pig kidney powder. Wherein, the aloe extract dried powder is produced by grinding after performing the concentration of the decolored aloe gel in a ratio of 200 to 1, and the pig kidney powder is obtained by drying and grinding to be powder. The present invention also provides a use of the medicine used to treat kidney failure and produced by aforementioned aloe/pig kidney composite composition. The aloe/pig kidney composite composition of the present invention can be used to treat kidney failure effectively.

Description

蘆薈豬腎複方組成物及其用於製造治療腎臟衰竭之醫藥品的用途Aloe porcine kidney compound composition and use thereof for manufacturing medicine for treating kidney failure

本發明涉及一種組成物,特別是蘆薈豬腎複方組成物。本發明另涉及一種用途,特別是指蘆薈豬腎複方組成物用於製造治療腎臟衰竭之醫藥品的用途。The present invention relates to a composition, particularly aloe vera pig kidney compound composition. The invention further relates to a use, in particular to the use of aloe vera porcine kidney composition for the manufacture of a medicament for the treatment of kidney failure.

腎功能衰竭(renal failure)又簡稱腎衰竭,主要是因為腎臟發生病變使得腎臟功能不完全,導致腎臟在過濾血液時未能有效將代謝廢物移除。其中腎衰竭又可分為急性腎衰竭與慢性腎衰竭,急性腎衰竭常見的症狀為尿少(成年每日尿液量少於400毫升),尤其在急重症病患較容易會遇到此種的併發症,因此造成較高的死亡;慢性腎衰竭是指持續三個月腎臟功能下降至60%以下,若長期罹患慢性臟病的患者,將可能會導致不可逆的腎臟損害。Renal failure, also referred to as renal failure, is mainly due to the incomplete renal function caused by kidney disease, which causes the kidney to fail to effectively remove metabolic waste when filtering blood. Renal failure can be divided into acute renal failure and chronic renal failure. The common symptoms of acute renal failure are oliguria (less than 400 ml of urine per day in adulthood), especially in patients with acute and severe disease. Complications, therefore, cause higher death; chronic renal failure refers to a decline in renal function to less than 60% for three months, and if it is chronically ill, it may cause irreversible kidney damage.

蘆薈為多年生草本且多肉植物,蘆薈除了具有保濕、曬後修復等美容功效外,蘆薈萃取物已知亦具有抗氧化、抗發炎、抑菌和促進傷口癒合的效果。現有技術中,如中國發明專利申請案公開公報第104873677號揭示一種治療慢性腎功能衰竭的中藥醋劑,取黃芪8份,熟大黃8份,紅花8份,蘆薈8份,蜂蜜8份,食醋60份。其中黃芪、熟大黃、紅花以乙醇回流提取後,再與蘆薈、蜂蜜、食醋加熱混合均勻製得。然而,該中藥醋劑之複方缺乏科學基礎證實所述之功效,且目前仍缺乏以蘆薈為主之複方用於治療腎衰竭的相關研究。Aloe vera is a perennial herbaceous and succulent plant. In addition to its beauty effects such as moisturizing and post-sun repair, aloe vera extract is known to have antioxidant, anti-inflammatory, antibacterial and wound healing effects. In the prior art, for example, Chinese Patent Application Publication No. 104873677 discloses a traditional Chinese medicine vinegar for treating chronic renal failure, taking 8 parts of astragalus, 8 parts of cooked rhubarb, 8 parts of safflower, 8 parts of eucalyptus, and 8 parts of honey. 60 parts of vinegar. Among them, Astragalus, cooked rhubarb and safflower are extracted by refluxing with ethanol, and then uniformly mixed with eucalyptus, honey and vinegar. However, the compound of the traditional Chinese medicine vinegar lacks the scientific basis to confirm the efficacy, and there is still a lack of aloe-based compound for the treatment of renal failure.

有鑑於此,如何發展出改善腎臟衰竭的組成物,現有技術實有待改善的必要。In view of this, how to develop a composition for improving kidney failure, the prior art needs to be improved.

為了克服現有技術之缺點,本發明的目的在於提供一種蘆薈豬腎複方組成物,以達成治療腎臟衰竭的功效。In order to overcome the disadvantages of the prior art, it is an object of the present invention to provide an aloe porcine kidney compound composition for achieving the efficacy of treating kidney failure.

為達到上述之發明目的,本發明提供一種蘆薈豬腎複方組成物,其包含蘆薈萃取物乾燥粉末以及豬腎粉末;其中蘆薈萃取物乾燥粉末為脫色蘆薈凝膠以200:1濃縮後乾燥研磨成粉,豬腎粉末為乾燥後研磨成粉。In order to achieve the above object, the present invention provides an aloe porcine kidney compound composition comprising aloe vera extract dry powder and pig kidney powder; wherein the aloe extract dried powder is a decolorized aloe gel, concentrated at 200:1, and then dried and ground into Powder, pig kidney powder is dried and ground into powder.

較佳的,所述之蘆薈萃取物乾燥粉末與豬腎粉末的重量比例介於1:1至2:1之間,包含端點值。Preferably, the weight ratio of the dried aloe extract powder to the porcine kidney powder is between 1:1 and 2:1, inclusive.

本發明另提供一種治療腎衰竭之醫藥品,其包含有效劑量之如請求項1或2所述之蘆薈豬腎複方組成物以及其藥學上可接受的載劑。The present invention further provides a pharmaceutical for treating renal failure comprising an effective amount of the aloe porcine kidney compound composition according to claim 1 or 2 and a pharmaceutically acceptable carrier thereof.

較佳的,所述之醫藥品係經腸道的或非經腸道的劑型。Preferably, the pharmaceutical product is an enteral or parenteral dosage form.

更佳的,所述之經腸道的劑型係口服劑型,其口服劑型係溶液、乳劑、懸浮液、粉末、錠劑、丸劑、口含錠、片劑、口嚼膠或膠囊。More preferably, the enteral dosage form is an oral dosage form, and the oral dosage form is a solution, an emulsion, a suspension, a powder, a lozenge, a pill, an ingot, a tablet, a chewing gum or a capsule.

本發明另提供一種如前述之蘆薈豬腎複方組成物用於製造治療腎衰竭之醫藥品的用途,其中醫藥品含有有效劑量之蘆薈豬腎複方組成物以及其藥學上可接受的載劑。The present invention further provides a use of the aloe vera porcine kidney composition as described above for the manufacture of a medicament for treating renal failure, wherein the medicament comprises an effective amount of an aloe porcine kidney compound composition and a pharmaceutically acceptable carrier thereof.

本發明的醫藥品係可利用熟習此技藝者所詳知的技術,將上述的蘆薈豬腎複方組成物與一藥學上可接受之載劑製備成一適用本發明之劑型。其中本發明所述之「醫藥上可接受之載劑」包含,但不限於水、醇(alcohols)、甘醇(glycol)、碳氫化合物(hydrocarbons)[諸如石油膠(petroleum jelly)以及白凡士林(white petrolatum)]、蠟(wax)[諸如石蠟(paraffin)以及黃蠟(yellow wax)]、保存劑(preserving agents)、抗氧化劑(antioxidants)、溶劑(solvent)、乳化劑(emulsifier)、懸浮劑(suspending agent)、分解劑(decomposer)、黏結劑(binding agent)、賦形劑(excipient)、安定劑(stabilizing agent)、螯合劑(chelating agent)、稀釋劑(diluent)、膠凝劑(gelling agent)、防腐劑(preservative)、潤滑劑(lubricant)、吸收增強劑(absorption enhancers)、活性劑(active agents)、保濕劑(humectants)、氣味吸收劑(odor absorbers)、香料(fragrances)、pH調整劑(pH adjusting agents)、閉塞劑(occlusive agents)、軟化劑(emollients)、增稠劑(thickeners)、助溶劑(solubilizing agents)、滲透增強劑(penetration enhancers)、抗刺激劑(anti-irritants)、著色劑(colorants)、推進劑(propellants)表面活性劑(surfactant),及其他類似或適用本發明之載劑。The pharmaceutical system of the present invention can be prepared into a dosage form suitable for the present invention by using the above-described aloe porcine kidney compound composition and a pharmaceutically acceptable carrier, using techniques well known to those skilled in the art. The "pharmaceutically acceptable carrier" as used in the present invention includes, but is not limited to, water, alcohols, glycols, hydrocarbons [such as petroleum jelly and white petrolatum). (white petrolatum)], wax (such as paraffin and yellow wax), preserving agents, antioxidants, solvents, emulsifiers, suspending agents (suspending agent), decomposer, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent Agent), preservative, lubricant, absorption enhancers, active agents, humectants, odor absorbers, fragrances, pH pH adjusting agents, occlusive agents, emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants s), colorants, propellants, surfactants, and other carriers similar or suitable for use in the present invention.

較佳的,所述之蘆薈豬腎複方組成物之人體有效劑量:蘆薈萃取物乾燥粉末介於每日每公斤0.13克(g/kg/day)至0.81 g/kg/day,豬腎粉末為0.13 g/kg/day至0.4 g/kg/day,且蘆薈萃取物乾燥粉末與豬腎粉末的重量比例介於1:1至2:1之間。以上劑量是根據2005年美國食品藥物管理局所公告之實驗初期估算方法(Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers)計算而得。Preferably, the effective dose of the aloe vera porcine kidney compound composition: aloe vera extract dry powder is between 0.13 g/g/kg/kg/kg/day per kg, and the pig kidney powder is 0.13 g/kg/day to 0.4 g/kg/day, and the weight ratio of aloe extract dry powder to pig kidney powder is between 1:1 and 2:1. The above dosages are calculated according to the Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.

更佳的,所述之蘆薈豬腎複方組成物之人體有效劑量:蘆薈萃取物乾燥粉末介於0.2 g/kg/day至0.41 g/kg/day,豬腎粉末為0.2 g/kg/day,且蘆薈萃取物乾燥粉末與豬腎粉末的重量比例介於1:1至2:1之間。More preferably, the effective dose of the aloe vera porcine kidney compound composition is: aloe extract dry powder is between 0.2 g/kg/day and 0.41 g/kg/day, and pig kidney powder is 0.2 g/kg/day. And the weight ratio of the aloe extract dry powder to the pig kidney powder is between 1:1 and 2:1.

較佳的,所述之腎衰竭,其形成途徑包含調控纖維化Smad (mothers against decapentaplegic)路徑蛋白表現(如:促進纖維化路徑因子p-Smad 3 (phosphorylated-mothers against decapentaplegic homolog 2) / Smad 3蛋白表現及Smad 4蛋白表現、抑制纖維化路徑因子p-Smad 2 / Smad 2蛋白表現)、促進發炎因子、降低總抗氧化能力(trolox equivalent antioxidant capacity,TEAC)、降低抗氧化酵素的活性或其組合。Preferably, said renal failure, the pathway of its formation comprises regulation of fibrotic Smad (mothers against decapentaplegic) pathway protein expression (eg, promoting fibrotic-mothers against decapentaplegic homolog 2) / Smad 3 Protein expression and Smad 4 protein expression, inhibition of fibrosis pathway factor p-Smad 2 / Smad 2 protein expression), promotion of inflammatory factors, reduction of total antioxidant capacity (TEAC), reduction of antioxidant enzyme activity or combination.

更佳的,所述之纖維化路徑因子包含,但不限於α-平滑肌肌動蛋白(α-smooth muscle actin,α-SMA)、纖連蛋白(fibronectin,FN)、胞漿素原活化因子抑制劑1 (plasminogen activactor inhibitor-1,PAI-1)、第一型膠原蛋白(Type 1 collagen,C-1)、結締組織生長因子(connective tissue growth factor,CTGF)、TGF-β1。More preferably, the fibrotic pathway factor comprises, but is not limited to, α-smooth muscle actin (α-SMA), fibronectin (FN), and plasminogen activator inhibition. 1 (plasminogen activactor inhibitor-1, PAI-1), type 1 collagen (C-1), connective tissue growth factor (CTGF), TGF-β1.

更佳的,所述之發炎因子包含,但不限於轉化生長因子β1(transforming growth factor-β1,TGF-β1)、核內因子-κB (nuclear factor-κB,NF-κB)、誘導型一氧化氮合成酶(inducible nitric oxide synthase,iNOS)、環加氧酶(cyclooxygenase 2,COX-2)、介白素-6 (interleukin-6,IL-6)及腫瘤壞死因子-α (tumor necrosis factor-α,TNF-α)。More preferably, the inflammatory factor comprises, but is not limited to, transforming growth factor-β1 (TGF-β1), nuclear factor-κB (NF-κB), and induced oxidation. Inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), interleukin-6 (IL-6), and tumor necrosis factor-α (tumor necrosis factor- α, TNF-α).

更佳的,所述之抗氧化酵素包含,但不限於過氧化氫酶活性(catalase)、穀胱甘肽(glutathione,GSH)、榖胱甘肽過氧化酶(glutathione peroxidase,GPx)、超氧化物歧化酶(superoxide dismutase,SOD)及榖胱甘肽還原酶(glutathione reductase,GRd)。More preferably, the antioxidant enzymes include, but are not limited to, catalase, glutathione (GSH), glutathione peroxidase (GPx), superoxide Superoxide dismutase (SOD) and glutathione reductase (GRd).

較佳的,所述之腎衰竭的症狀包含腎纖維化。Preferably, the symptom of renal failure comprises renal fibrosis.

本發明的優點在於本發明之蘆薈豬腎複方組成物可改善腎衰竭,尤其是慢性腎纖維化;蘆薈豬腎複方組成物藉由抑制TGF-β1蛋白結合膜上受器後,啟動促纖維化Smad路徑蛋白表現、抑制纖維化路徑因子、抑制發炎因子進而達到抗腎纖維化的功效;此外,蘆薈豬腎複方組成物亦可提升總抗氧化能力、提升抗氧化酵素的活性的功效。The invention has the advantages that the aloe porcine kidney compound composition of the invention can improve renal failure, especially chronic renal fibrosis; the aloe porcine kidney compound composition initiates profibrosis by inhibiting the receptor on the TGF-β1 protein binding membrane. Smad pathway protein expression, inhibition of fibrosis pathway factors, inhibition of inflammatory factors to achieve anti-renal fibrosis; in addition, aloe vera porcine kidney compound composition can also enhance the overall antioxidant capacity, enhance the activity of antioxidant enzymes.

以下配合圖式及本發明之較佳實施例,進一步闡述本發明為達成目的所採取的技術手段。The technical means adopted by the present invention for achieving the object are further explained below in conjunction with the drawings and the preferred embodiments of the present invention.

製備例1 蘆薈萃取物(Aloe vera )之製備Preparation Example 1 Preparation of Aloe Vera Extract ( Aloe vera )

本發明所使用蘆薈萃取物是由中國河南九福來科技集團股份有限公司所提供脫色蘆薈凝膠200公斤濃縮提煉成1公斤(簡稱200:1)的蘆薈萃取物乾燥粉末(簡稱AV),其商品名稱為「蘆薈精粉膠囊」,型號為第四代富含10%蘆薈多醣的分離保活產品。其中蘆薈萃取物乾燥粉末的萃取方法揭示於中國發明專利申請案公開公報第103554294號,並使用去皮蘆薈進行萃取。The aloe extract used in the present invention is a dried extract of aloe extract (abbreviated as AV) which is obtained by decolorizing aloe vera gel 200 kg provided by China Jiufulai Technology Group Co., Ltd. of China, and is refined into 1 kg (referred to as 200:1). The product name is "Aloe Vera Powder Capsule", the model is the fourth generation of separation and preservation products rich in 10% aloe polysaccharide. The extraction method of the aloe extract dry powder is disclosed in Chinese Patent Application Publication No. 103554294, and is extracted using peeled aloe.

製備例2 豬腎粉末(pig kidney)之製備Preparation 2 Preparation of pig kidney powder

由市場購得之豬腎洗淨後切厚片以100ºC沸水川燙5分鐘,再流水洗淨置於-80ºC冰箱冷凍1天,而後取出進行冷凍乾燥,待豬腎徹底脫水乾燥後再以均質機研磨成粉末,即獲得豬腎粉末(簡稱PK),分裝存放於乾燥箱備用。The pig kidneys purchased from the market are washed and cut into thick slices and boiled in 100oC boiling water for 5 minutes. The water is washed and placed in a -80oC refrigerator for 1 day, and then taken out for freeze-drying. After the pig kidney is completely dehydrated and dried, it is homogenized. The machine is ground into a powder, that is, pig kidney powder (referred to as PK) is obtained, and stored in a dry box for storage.

實施例1 蘆薈豬腎複方組成物對於腺嘌呤(adenine)誘發後小鼠體重變化之影響Example 1 Effect of aloe porcine kidney compound composition on body weight change of adenine induced mice

將6週齡雄性C57BL/6小鼠入室後,飼養條件為自動空氣調節(換氣率每小時12次),自動光照控制(12小時白晝、12小時黑夜)、平均室溫22±2ºC、相對溼度50%至55%、自由進食之一般飼料(臺灣樂斯科生物科技股份有限公司購買編號MFG22,如下表1)與飲水。 表1、MFG22飼料組成 After 6 weeks old male C57BL/6 mice were placed in the room, the feeding conditions were automatic air conditioning (air exchange rate 12 times per hour), automatic light control (12 hours daylight, 12 hours dark night), average room temperature 22±2oC, relative Humidity 50% to 55%, free to eat the general feed (Taiwan Lesco Biotechnology Co., Ltd. purchase number MFG22, as shown in Table 1 below) and drinking water. Table 1, MFG22 feed composition

待動物適應環境7天後,將其隨機分配為六組(8隻/組): (1)控制組:標準飼料,正常飲食。 (2)誘導組(adenine 0.2%):標準飼料添加重量百分比為0.2% (w/w)腺嘌呤。 (3)低劑量蘆薈合併豬腎試驗組(adenine 0.2%+AV 1%+PK 1%):標準飼料添加0.2% (w/w)腺嘌呤、取製備例1之1% (w/w)蘆薈萃取物乾燥粉末(AV 1%)、取製備例2之1% (w/w)豬腎粉末(PK 1%)。 (4)高劑量蘆薈合併豬腎試驗組(adenine 0.2%+AV 2%+PK 1%):標準飼料添加0.2% (w/w)腺嘌呤、取製備例1之2% (w/w)蘆薈萃取物乾燥粉末(AV 2%)以及取製備例2之1% (w/w)豬腎粉末(PK 1%)。 (5)單獨蘆薈試驗組(adenine 0.2%+AV 2%):標準飼料添加0.2% (w/w)腺嘌呤及取製備例1之2% (w/w)蘆薈萃取物乾燥粉末(AV 2%)。 (6)單獨豬腎試驗組(adenine 0.2%+PK 1%):標準飼料#MFG22添加0.2% (w/w)腺嘌呤以及1% (w/w)豬腎粉末(PK 1%)。After the animals were acclimated to the environment for 7 days, they were randomly assigned to six groups (8/group): (1) Control group: standard feed, normal diet. (2) Induction group (adenine 0.2%): The standard feed was added in an amount of 0.2% (w/w) adenine. (3) Low-dose aloe vera combined with pig kidney test group (adenine 0.2%+AV 1%+PK 1%): 0.2% (w/w) adenine was added to standard feed, and 1% (w/w) of preparation example 1 was taken. Aloe extract dry powder (AV 1%), 1% (w/w) pig kidney powder of Preparation Example 2 (PK 1%). (4) High-dose aloe vera combined with pig kidney test group (adenine 0.2%+AV 2%+PK 1%): 0.2% (w/w) adenine was added to standard feed, and 2% (w/w) of preparation example 1 was taken. Aloe extract dry powder (AV 2%) and 1% (w/w) porcine kidney powder (PK 1%) of Preparation Example 2. (5) Aloe vera test group alone (adenine 0.2%+AV 2%): 0.2% (w/w) adenine in standard feed and 2% (w/w) aloe extract dry powder (AV 2) of Preparation Example 1 %). (6) Individual pig kidney test group (adenine 0.2% + PK 1%): Standard feed #MFG22 was added with 0.2% (w/w) adenine and 1% (w/w) pig kidney powder (PK 1%).

實驗過程中每隻小鼠平均每天飲食攝入約5公克,其飲食中除了控制組外皆含有0.2% (w/w)腺嘌呤(即0.01克腺嘌呤/隻/天),並將AV 1% (0.05克AV/隻/天)、AV 2% (0.1克AV/隻/天)或PK 1% (0.05克PK/隻/天)依上述不同組別之劑量拌入粉狀飼料製成團狀餵食小鼠。除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV與PK依劑量不同分別拌於標準飼料中合併治療6週。實驗期間體重採每週監測持續至第10週實驗結束,於每週二測量老鼠體重並紀錄。 表2、各組小鼠第2至10週的體重數值(克) 註:統計為平均值±標準差(n = 8);## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。During the experiment, each mouse consumed an average of about 5 grams per day. In addition to the control group, the diet contained 0.2% (w/w) adenine (0.01 g of adenine/day/day) and AV 1 % (0.05 g AV / only / day), AV 2% (0.1 g AV / only / day) or PK 1% (0.05 g PK / only / day) made of powdered feed mixed in the above different groups The mice were fed in groups. In addition to the control group, after feeding for 0.2% (w/w) adenine every day for 4 weeks, AV and PK were mixed in standard diet for 6 weeks. Weekly monitoring of body weight during the experiment continued until the end of the experiment at week 10, and the body weight of the rats was measured and recorded on Tuesday. Table 2. Body weight values for the 2nd to 10th week of each group of mice (g) Note: The statistics are mean ± standard deviation (n = 8); ## p<0.01 is compared with the control group; * P < 0.05, ** P < 0.01 compared with the induction group.

體重數值如圖1與上表2所示,誘導組餵食腺嘌呤後體重顯著降低,誘導組與控制組相比在第五週至第十週分別下降為控制組的0.81、0.72、0.67、0.67、0.7、0.68倍。於第四週結束開始餵食不同劑量之治療藥物後,從體重數值可以發現adenine 0.2%+AV 2%+PK 1%試驗組在第6至10週顯著增加,與誘導組相比分別增加1.18、1.16、1.13、1.1及1.15倍。adenine 0.2%+AV 1%+PK 1%試驗組與誘導組相比則無差異。adenine 0.2%+AV 2%試驗組與誘導組相比,在第5週及第10週分別增加0.92及1.1倍。adenine 0.2%+PK 1%試驗組與誘導組相比,在第5週及第7至8週分別增加0.89、0.92及0.93倍。因此,蘆薈豬腎複方組成物具恢復體重之效果,且於第6至9週具有相乘效果(synergistic effect)。The body weight values are shown in Figure 1 and Table 2 above. The body weight of the induction group was significantly decreased after feeding adenine. The induction group decreased from 0.81, 0.72, 0.67, and 0.67 in the control group to the control group from the fifth week to the tenth week. 0.7, 0.68 times. After the treatment of different doses of the therapeutic drug at the end of the fourth week, the adenine 0.2%+AV 2%+PK 1% test group was significantly increased from the 6th to the 10th week, and increased by 1.18 compared with the induction group. 1.16, 1.13, 1.1 and 1.15 times. There was no difference between the adenine 0.2%+AV 1%+PK 1% test group and the induction group. The adenine 0.2%+AV 2% test group increased by 0.92 and 1.1 fold, respectively, at weeks 5 and 10 compared with the induction group. The adenine 0.2%+PK 1% test group increased by 0.89, 0.92, and 0.93 times at 5 weeks and 7 to 8 weeks, respectively, compared with the induction group. Therefore, the aloe porcine kidney compound composition has the effect of restoring body weight and has a synergistic effect at weeks 6 to 9.

實施例2 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠血清生化數值變化之影響Example 2 Effect of aloe porcine kidney compound composition on serum biochemical changes in mice induced by adenine

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後,犧牲動物取其血液並靜置30分鐘,利用超高速離心機以3000轉(rpm)、4ºC、15分鐘的條件離心並抽取上清液及血清進行實驗分析。 表3、血清生化數值 註:統計為平均值±標準差(n = 8);## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較;其中BUM (blood urea nitrogen)為血中尿素氮;CRE (creatinine)為肌酸酐;BS (blood sugar)為血糖;GOT (glutamic oxaloacetic transaminase)為麩氨基酸草醋酸轉氨基酶;GPT (glutamic pyruvic transaminase)為麩胺酸丙酮酸轉胺酶;TCHO (total cholesterol)為總膽固醇;TG (triglyceride)為三酸甘油脂。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks. At the end of the experiment, the animals were sacrificed to take the blood and allowed to stand for 30 minutes. The cells were centrifuged at 3000 rpm, 4 ° C, 15 minutes using an ultra-high speed centrifuge, and the supernatant and serum were extracted for experiment. analysis. Table 3, serum biochemical values Note: The statistics are mean ± standard deviation (n = 8); ## p<0.01 is compared with the control group; * P < 0.05, ** P < 0.01 compared with the induction group; BUM (blood urea nitrogen ) is blood urea nitrogen; CRE (creatinine) is creatinine; BS (blood sugar) is blood sugar; GOT (glutamic oxaloacetic transaminase) is bran amino acid grass acetic acid transaminase; GPT (glutamic pyruvic transaminase) is glutamic acid pyruvate Transaminase; TCHO (total cholesterol) is total cholesterol; TG (triglyceride) is triglyceride.

結果如上表3所示,於腎臟功能評估BUN與CRE結果顯示,誘導組於餵食腺嘌呤後可使BUN和CRE上升,與控制組相比分別上升3.47、2.7倍,皆達顯著差異,於adenine 0.2%+AV 1%+PK 1%或adenine 0.2%+AV 2%+PK 1%試驗組與誘導組相比,在BUN和CRE有下降之趨勢,而adenine 0.2%+AV 2%試驗組和adenine 0.2%+PK 1%試驗組與誘導組相比,在BUN和CRE則無明顯差異。血糖數值評估方面,誘導組與控制組相比較後未達統計差異,但於adenine 0.2%+AV 2%試驗組或adenine 0.2%+PK 1%試驗組與誘導組相比,則分別顯著上升1.41、1.36倍。在肝臟功能性評估GOT與GPT結果顯示,誘導組與控制組相比、或者不同劑量的AV及/或PK的試驗組與誘導組相比較,皆未達統計上差異。於脂質代謝評估TCHO與TG,誘導組與控制組相比較,TCHO增加1.28倍,TG有下降的趨勢,於adenine 0.2%+AV 1%+PK 1%試驗組與誘導組相比,TCHO顯著上升1.1倍,TG則未達顯著差異,於adenine 0.2%+AV 2%+PK 1%試驗組、adenine 0.2%+AV 2%試驗組或adenine 0.2%+PK 1%試驗組,在TCHO與TG皆無統計上顯著差異。因此,蘆薈豬腎複方組成物可降低BUN且具有相乘效果。The results are shown in Table 3 above. BUN and CRE results in renal function evaluation showed that BUN and CRE increased in the induction group after feeding adenine, which was 3.47 and 2.7 times higher than that in the control group, respectively, and both showed significant differences in adenine. 0.2%+AV 1%+PK 1% or adenine 0.2%+AV 2%+PK 1% compared with the induction group, the BUN and CRE showed a decreasing trend, while the adenine 0.2%+AV 2% test group and There was no significant difference in BUN and CRE between the adenine 0.2%+PK 1% test group and the induction group. In terms of blood glucose evaluation, the induction group did not reach statistical difference after comparison with the control group, but the adenine 0.2%+AV 2% test group or the adenine 0.2%+PK 1% test group increased significantly by 1.41 compared with the induction group. , 1.36 times. In the liver functional assessment GOT and GPT results showed that the induction group compared with the control group, or different doses of AV and / or PK test group compared with the induction group, did not reach statistical differences. Compared with the control group, the TCHO increased by 1.28 times and the TG decreased with the lipid metabolism. Compared with the induction group, the TCHO increased significantly in the adenine 0.2%+AV 1%+PK 1% test group. 1.1 times, TG did not reach significant difference, in adenine 0.2% + AV 2% + PK 1% test group, adenine 0.2% + AV 2% test group or adenine 0.2% + PK 1% test group, neither TCHO nor TG Statistically significant differences. Therefore, the aloe porcine kidney compound composition can reduce BUN and have a multiplication effect.

實施例3 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟抗氧化酵素與脂質過氧化程度之影響Example 3 Effect of Aloe Pig and Kidney Compound Composition on Antioxidant Enzyme and Lipid Peroxidation in Kidney of Mice Induced by Adenine

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織進行分析。 表4、腎臟抗氧化酵素活性與脂質過氧化程度 註:統計為平均值±標準差(n = 8);# p<0.05、## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較;TEAC activity (trolox equivalent antioxidant capacity)為總抗氧化能力(nmol/蛋白質mg);catalase活性為過氧化氫酶活性(過氧化氫消耗量mmol/蛋白質mg);MDA (malondialdehyde)濃度為丙二醛濃度(nmol/蛋白質mg);GSH (glutathione)濃度為穀胱甘肽濃度(μM/蛋白質mg);GPx (glutathione peroxidase)活性為榖胱甘肽過氧化酶活性[被氧化之菸鹼醯胺腺嘌呤二核苷酸磷酸(NADPH) nmol/分鐘/蛋白質mg];SOD (superoxide dismutase)活性為超氧化物歧化酶活性(U/ml/蛋白質mg);GRd (glutathione reductase)活性為榖胱甘肽還原酶活性(NADPH nmol/分鐘/毫升/蛋白質mg);IL-1β (interleukin-1β)為介白素-1β (pg/ml);IL-6 (interleukin-6)為介白素-6 (pg/ml);TNF-α (tumor necrosis factor-α)為腫瘤壞死因子-α (pg/ml)。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks, and the mouse kidney tissue was taken for analysis after the end of the experiment. Table 4. Renal antioxidant enzyme activity and lipid peroxidation Note: The statistics are mean ± standard deviation (n = 8); # p < 0.05, ## p < 0.01 compared with the control group; * P < 0.05, ** P < 0.01 compared with the induction group; TEAC Activity (trolox equivalent antioxidant capacity) is the total antioxidant capacity (nmol / protein mg); catalase activity is catalase activity (hydrogen peroxide consumption mmol / protein mg); MDA (malondialdehyde) concentration is malondialdehyde concentration ( Nmol/protein mg); GSH (glutathione) concentration is glutathione concentration (μM/protein mg); GPx (glutathione peroxidase) activity is glutathione peroxidase activity [oxidized nicotine guanamine adenine II Nucleotide Phosphate (NADPH) nmol/min/protein mg]; SOD (superoxide dismutase) activity is superoxide dismutase activity (U/ml/protein mg); GRd (glutathione reductase) activity is glutathione reductase Activity (NADPH nmol/min/ml/protein mg); IL-1β (interleukin-1β) is interleukin-1β (pg/ml); IL-6 (interleukin-6) is interleukin-6 (pg/) Ml); TNF-α (tumor necrosis factor-α) is tumor necrosis factor-α (pg/ml).

結果如上表4所示,腎臟抗氧化酵素分析,與控制組相比較,誘導組可以顯著減少抗氧化酵素如:catalase、GSH、SOD及GRd分別減少為控制組的0.77、0.47、0.48及0.74倍,於TEAC和GPx則無顯著差異。於adenine 0.2%+AV 1%+PK 1%試驗組與誘導組相較,能顯著增加抗氧化酵素如:TEAC、catalase、GSH、SOD及GRd分別增加1.19、1.71、3.04、1.3及1.21倍,但在GPx則無統計上顯著差異。在AV 2%+PK 1%試驗組與誘導組相較,能夠顯著上升TEAC、catalase、GSH、GPx、SOD及GRd,分別上升1.09、1.57、1.65、1.63、1.46及1.25倍。adenine 0.2%+AV 2%試驗組與誘導組相比較,則可以顯著增加TEAC、catalase、GSH、GPx、SOD及GRd,分別增加1.12、1.58、2.4、1.84、1.49及1.4倍。而在adenine 0.2%+PK 1%試驗組與誘導組相比較,GSH及GRd顯著地分別上升2.04及1.34倍、於GPx與SOD有增加的趨勢但未達顯著差異、而TEAC和catalase未有統計上顯著差異。The results are shown in Table 4 above. Compared with the control group, the antioxidant group in the kidney group can significantly reduce the antioxidant enzymes such as: catalase, GSH, SOD and GRd to 0.77, 0.47, 0.48 and 0.74 times of the control group, respectively. There was no significant difference between TEAC and GPx. Compared with the induction group, the adenine 0.2%+AV 1%+PK 1% test group significantly increased the antioxidant enzymes such as TEAC, catalase, GSH, SOD and GRd by 1.19, 1.71, 3.04, 1.3 and 1.21 times, respectively. However, there is no statistically significant difference in GPx. Compared with the induction group, the AV 2%+PK 1% test group significantly increased TEAC, catalase, GSH, GPx, SOD and GRd, which increased by 1.09, 1.57, 1.65, 1.63, 1.46 and 1.25 times, respectively. Compared with the induction group, the adenine 0.2%+AV 2% test group significantly increased TEAC, catalase, GSH, GPx, SOD and GRd by 1.12, 1.58, 2.4, 1.84, 1.49 and 1.4 times, respectively. Compared with the induction group, GSH and GRd increased significantly by 2.04 and 1.34 times in the adenine 0.2%+PK 1% test group, but increased in GPx and SOD but did not reach significant difference, while TEAC and catalase had no statistics. Significant differences.

腎臟脂質過氧化程度(thiobarbituric acid reactive substances,TBARs)主要參考學者Ohkawa於1979年所建立的方法進行分析,請參閱上表4,誘導組與控制組相比,脂質過氧化程度指標MDA生成顯著增加1.16倍,而adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組與誘導組相比較分別減少為誘導組的0.58、0.67倍的MDA生成,而adenine 0.2%+AV 2%試驗組或者adenine 0.2%+PK 1%試驗組與誘導組相比較則無統計上顯著差異。因此,蘆薈豬腎複方組成物可顯著降低脂質過氧化程度。The thiobarbituric acid reactive substances (TBARs) were mainly analyzed by the method established by the scholar Ohkawa in 1979. Please refer to Table 4 above. Compared with the control group, the MDA production of the lipid peroxidation index was significantly increased. 1.16 times, while adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+PK 1% test group was reduced to 0.58 and 0.67 times MDA production in the induction group compared with the induction group, respectively. There was no statistically significant difference in the adenine 0.2%+AV 2% test group or the adenine 0.2%+PK 1% test group compared with the induction group. Therefore, the aloe porcine kidney compound composition can significantly reduce the degree of lipid peroxidation.

實施例4 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟發炎因子之影響Example 4 Effect of aloe porcine kidney compound composition on adenine-induced renal inflammatory factors in mice

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織進行分析。 表5、腎臟細胞激素含量測定 註:統計為平均值±標準差(n = 8);# p<0.05、## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較;IL-1β (interleukin-1β)為介白素-1β (pg/ml);IL-6 (interleukin-6)為介白素-6 (pg/ml);TNF-α (tumor necrosis factor-α)為腫瘤壞死因子-α (pg/ml)。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks, and the mouse kidney tissue was taken for analysis after the end of the experiment. Table 5. Determination of renal cytokine levels Note: The statistical mean ± standard deviation (n = 8); # p <0.05, ## p <0.01 compared with the control group; * P <0.05, ** P <0.01 as compared with the induced group; of IL -1β (interleukin-1β) is interleukin-1β (pg/ml); IL-6 (interleukin-6) is interleukin-6 (pg/ml); TNF-α (tumor necrosis factor-α) is Tumor necrosis factor-α (pg/ml).

結果如上表5所示,與控制組相比較,誘導組可以增加IL-6與TNF-α之表現,分別上升3.04、1.98倍,於統計上又以IL-6增加最為顯著,於IL-1β雖有增加的趨勢,但未達顯著。而合併處理的組別,adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組,與誘導組相比,IL-6分別可以降低0.34、0.41倍,TNF-α則分別可以降低為誘導組的0.56、0.5倍,於IL-1β僅adenine 0.2%+AV 2%+PK 1%試驗組有降低的趨勢且具有相乘效果。而adenine 0.2%+AV 2%試驗組與誘導組相比較,可以降低IL-6與TNF-α分別為為誘導組的0.28、0.45倍;在adenine 0.2%+PK 1%試驗組與誘導組相比較,則可以減少腎臟IL-6與TNF-α表現分別為為誘導組的0.24、0.55倍。由以上結果可以得知AV和PK不論是複方或者單獨處理,都具有降低發炎反應的能力。The results are shown in Table 5 above. Compared with the control group, the induction group increased the expression of IL-6 and TNF-α, which increased by 3.04 and 1.98 times, respectively. Statistically, the increase in IL-6 was most significant in IL-1β. Although there is an increasing trend, it has not reached significant. The combined treatment group, adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+PK 1% test group, IL-6 can be reduced by 0.34, 0.41 compared with the induction group.倍, TNF-α can be reduced to 0.56, 0.5 times of the induction group, respectively, in IL-1β only adenine 0.2% + AV 2% + PK 1% test group has a decreasing trend and has a multiplication effect. Compared with the induction group, the adenine 0.2%+AV 2% test group can reduce the IL-6 and TNF-α by 0.28 and 0.45 times, respectively; in the adenine 0.2%+PK 1% test group and the induction group. By comparison, the expression of IL-6 and TNF-α in the kidneys was reduced to 0.24 and 0.55 times, respectively, in the induction group. From the above results, it can be known that AV and PK have the ability to reduce the inflammatory response whether it is a combination or a separate treatment.

實施例5 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟重量及病理切片之影響Example 5 Effect of aloe porcine kidney compound composition on adenine-induced kidney weight and pathological section in mice

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織進行分析。小鼠犧牲後取其腎臟進行蘇木素-伊紅染色與纖維化染色於腎臟染片中主要以腎絲球為中心並使用100倍之倍率拍攝,於顯微鏡下觀察切片有無腎損傷的病理特徵。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks, and the mouse kidney tissue was taken for analysis after the end of the experiment. After the sacrifice of the mice, the kidneys were subjected to hematoxylin-eosin staining and fibrosis staining. The kidney stained with the kidney spheroids and photographed at 100 times magnification. The pathological features of the kidneys were observed under the microscope.

請參閱圖2所示,最上排為小鼠犧牲當下所拍攝的腎臟影像,由照片可以觀察到,控制組腎臟的色澤較為紅潤且具有光澤,此為健康腎臟的表徵。誘導組與控制組相較之下,明顯無紅潤的色澤且表面有明顯的突起顆粒均勻散佈在整個腎臟表面,觸感較為粗糙。於adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組與誘導組相比,腎臟表面之突起顆粒較為減少,體觸感細緻也比較有光澤感,色澤部分以adenine 0.2%+AV 2%+PK 1%試驗組較為紅潤有光澤。於adenine 0.2%+AV 2%試驗組或者adenine 0.2%+PK 1%試驗組與誘導組相比,體觸感同樣較為平滑。由圖3腎臟質量分析結果得知,誘導組相較於控制組減少0.37倍,有顯著萎縮的現象,而adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組與誘導組相比,腎臟質量明顯增加,分別增加1.65、1.5倍,而adenine 0.2%+AV 2%試驗組或者adenine 0.2%+PK 1%試驗組與誘導組相比有增加的趨勢。Please refer to Figure 2, the top row is the kidney image taken by the mouse at the moment of sacrifice. It can be observed from the photo that the color of the kidney in the control group is more rosy and shiny, which is a characteristic of healthy kidney. Compared with the control group, the induction group showed no ruddy color and obvious protruding particles on the surface of the whole kidney surface, and the touch was rough. In the adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+PK 1% test group, compared with the induction group, the surface of the kidney has less protruding particles, and the body touch is more delicate and shiny. Sense, color part with adenine 0.2% + AV 2% + PK 1% test group is more rosy and shiny. In the adenine 0.2%+AV 2% test group or the adenine 0.2%+PK 1% test group, the body touch was also smoother than the induction group. According to the results of kidney quality analysis in Figure 3, the induction group was 0.37 times smaller than the control group, and there was significant atrophy, while adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+ Compared with the induction group, the PK 1% test group increased the kidney mass by 1.65 and 1.5 times, respectively, while the adenine 0.2%+AV 2% test group or the adenine 0.2%+PK 1% test group increased compared with the induction group. the trend of.

請參閱圖2所示,第二排為纖維化染色,若組織有纖維化現象則染色結果會呈現出藍色。結果顯示,控制組無纖維化現象,而誘導組則有明顯的纖維化現象。於adenine 0.2%+AV 1%+PK 1%試驗組、adenine 0.2%+AV 2%+PK 1%試驗組、adenine 0.2%+AV 2%試驗組、或adenine 0.2%+PK 1%試驗組與誘導組相比較,其纖維化現象減少,其中又以蘆薈豬腎複方組成物改善腎損傷效果較為明顯。Referring to Figure 2, the second row is fibrillated. If the tissue is fibrotic, the staining results will appear blue. The results showed that there was no fibrosis in the control group and significant fibrosis in the induction group. In adenine 0.2%+AV 1%+PK 1% test group, adenine 0.2%+AV 2%+PK 1% test group, adenine 0.2%+AV 2% test group, or adenine 0.2%+PK 1% test group Compared with the induction group, the fibrosis phenomenon was reduced, and the effect of aloe vera pig kidney compound composition on improving kidney damage was obvious.

請參閱圖2所示,第三排蘇木素-伊紅染色結果顯示,控制組腎絲球體內之間隙囊狀空間較小,且周圍腎小管其管腔內的上皮細胞排列較為規則且緻密,而細胞型態較為緊緻飽滿,管腔內的空間暢通無任何代謝物沉積的現象,100倍視野下的腎小管整體而言數量分布較為密集完整,此為健康腎小管上皮細胞的病理切片特徵。誘導組與控制組相比,可以發現餵食腺嘌呤,會造成腎絲球體內之間隙囊狀空間變大,且分布在腎絲球周圍的腎小管上皮細胞數減少且形態扁平,使得腎小管的管徑擴大甚至瓦解,管腔亦可以觀察到腺嘌呤代謝產物2,8-二羥基腺嘌呤黃色結晶體沉積,於100倍視野下的腎小管分布也明顯較稀疏。而adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組與誘導組比較,可以發現100倍視野下的腎小管分布明顯增加,細胞型態飽滿,管腔上皮細胞的排列也較為緻密,2,8-二羥基腺嘌呤黃色結晶體沉積相對減少,但在腎絲球內之間隙囊狀空間則沒有明顯差異。於adenine 0.2%+PK 1%試驗組與誘導組相比較能明顯改善腎損傷的病理特徵,而adenine 0.2%+AV 2%試驗組與誘導組相比較則無明顯差異。因此,蘆薈豬腎複方組成物可顯著改善腎損傷的病理特徵。Referring to Figure 2, the results of the third row of hematoxylin-eosin staining showed that the saccular space in the renal spheroid of the control group was small, and the epithelial cells in the lumen of the surrounding renal tubules were regular and dense. The cell type is tight and full, and the space in the lumen is clear without any metabolite deposition. The number of renal tubules in the 100-fold field of view is dense and complete as a whole, which is a pathological feature of healthy renal tubular epithelial cells. Compared with the control group, the induction group can be found that feeding adenine will cause the saccular space in the renal spheroid to become larger, and the number of renal tubular epithelial cells distributed around the renal spheroid is reduced and the shape is flat, making the renal tubule The diameter of the tube is enlarged or even disintegrated, and the adenine metabolite 2,8-dihydroxyadenine yellow crystal deposit can be observed in the lumen, and the distribution of renal tubules in the 100-fold field of view is also significantly sparse. The adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+PK 1% test group compared with the induction group, the renal tubular distribution in the 100-fold field of view was significantly increased, and the cell type was full. The arrangement of luminal epithelial cells was also dense, and the deposition of 2,8-dihydroxyadenine yellow crystals was relatively reduced, but there was no significant difference in the interstitial saccular space in the glomeruli. Compared with the induction group, the adenine 0.2%+PK 1% test group can significantly improve the pathological features of renal injury, while the adenine 0.2%+AV 2% test group has no significant difference compared with the induction group. Therefore, the aloe porcine kidney compound composition can significantly improve the pathological features of kidney injury.

實施例6 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟中纖維化蛋白TGF-β1表現之影響Example 6 Effect of aloe porcine kidney compound composition on the expression of fibrin TGF-β1 in the kidney of mice induced by adenine

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織,並以西方墨點法(western blotting)分析進行分析。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks. At the end of the experiment, the kidney tissue of the mice was taken and analyzed by western blotting analysis.

由圖4及圖5結果得知,誘導組可以增強TGF-β1蛋白表現,與控制組相比較增加8.48倍。adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組相較於誘導組可以顯著減少TGF-β1蛋白表現分別為誘導組的0.43、0.32倍,其中以adenine 0.2%+AV 2%+PK 1%試驗組降低TGF-β1蛋白表現最為顯著,而adenine 0.2%+AV 2%試驗組或者adenine 0.2%+PK 1%試驗組,有降低TGF-β1蛋白表現的趨勢。因此,蘆薈豬腎複方組成物可顯著降低纖維化相關蛋白的表現。From the results of Fig. 4 and Fig. 5, the induction group can enhance the expression of TGF-β1 protein, which is 8.48 times more than that of the control group. Adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+PK 1% test group can significantly reduce the expression of TGF-β1 protein by 0.43, 0.32 times compared with the induction group, respectively. Among them, adenine 0.2%+AV 2%+PK 1% test group showed the most significant decrease in TGF-β1 protein, while adenine 0.2%+AV 2% test group or adenine 0.2%+PK 1% test group had decreased TGF-β1. The trend in protein expression. Therefore, the aloe porcine kidney compound composition can significantly reduce the performance of fibrosis-related proteins.

實施例7 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟中Smad傳遞路徑相關蛋白表現之影響Example 7 Effect of aloe porcine kidney compound composition on the expression of Smad transmission pathway-related proteins in adenine-induced mouse kidney

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織,並以西方墨點法進行分析由TGF-β1蛋白結合膜上受器所啟動促纖維化Smad路徑蛋白表現。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks. At the end of the experiment, the kidney tissue of the mice was taken and analyzed by Western blotting method. The pro-fibrotic Smad pathway protein was activated by the receptor on the TGF-β1 protein binding membrane.

由圖6及圖7結果顯示,誘導組與控制組相比較,p-Smad2/Smad 2蛋白表現比率顯著減少為控制組的0.63倍,於adenine 0.2%+AV 2%+PK 1%試驗組則是顯著增加1.83倍,且具有相乘效果。而adenine 0.2%+AV 1%+PK 1%試驗組、adenine 0.2%+AV 2%試驗組、或adenine 0.2%+PK 1%試驗組與誘導組相比,皆無統計上顯著差異。圖8及圖9結果顯示,誘導組與控制組相比較,p-Smad 3/ Smad 3蛋白表現比率顯著上升1.77倍,於adenine 0.2%+AV 1%+PK 1%試驗組、adenine 0.2%+AV 2%+PK 1%試驗組、adenine 0.2%+AV 2%試驗組、或adenine 0.2%+PK 1%試驗組與誘導組相比,皆可以顯著減少p-Smad 3/ Smad 3蛋白表現比率,分別減少為誘導組的0.29、0.42、0.52、0.35倍,其中以adenine 0.2%+AV 1%+PK 1%試驗組最為顯著。圖10及圖11可以發現誘導組與控制組相比,Smad 4蛋白表現顯著增加1.55倍。於adenine 0.2%+AV 1%+PK 1%試驗組、adenine 0.2%+AV 2%+PK 1%試驗組、adenine 0.2%+AV 2%試驗組、或adenine 0.2%+PK 1%試驗組與誘導組相比,皆無統計上差異。因此,蘆薈豬腎複方組成物可顯著增加p-Smad2/Smad 2蛋白表現比率,並可顯著減少p-Smad 3/ Smad 3蛋白表現比率。From Fig. 6 and Fig. 7, the results showed that the p-Smad2/Smad 2 protein expression ratio was significantly reduced to 0.63 times that of the control group compared with the control group, and in the adenine 0.2%+AV 2%+PK 1% test group. It is a significant increase of 1.83 times and has a multiplication effect. There was no statistically significant difference in the adenine 0.2%+AV 1%+PK 1% test group, the adenine 0.2%+AV 2% test group, or the adenine 0.2%+PK 1% test group compared with the induction group. The results in Figure 8 and Figure 9 show that the p-Smad 3/Smad 3 protein expression ratio increased significantly by 1.77 times compared with the control group, in adenine 0.2%+AV 1%+PK 1% test group, adenine 0.2%+ The AV 2%+PK 1% test group, the adenine 0.2%+AV 2% test group, or the adenine 0.2%+PK 1% test group significantly reduced the p-Smad 3/Smad 3 protein performance ratio compared with the induction group. The reduction was 0.29, 0.42, 0.52, and 0.35 times of the induction group, respectively, and the test group was most prominent with adenine 0.2%+AV 1%+PK 1%. Figures 10 and 11 show that the induction group showed a significant 1.55 fold increase in Smad 4 protein performance compared to the control group. In adenine 0.2%+AV 1%+PK 1% test group, adenine 0.2%+AV 2%+PK 1% test group, adenine 0.2%+AV 2% test group, or adenine 0.2%+PK 1% test group There were no statistical differences in the induction group. Therefore, the aloe porcine kidney compound composition can significantly increase the p-Smad2/Smad 2 protein expression ratio and significantly reduce the p-Smad 3/Smad 3 protein expression ratio.

實施例8 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟中纖維化路徑相關蛋白表現之影響Example 8 Effect of aloe porcine kidney compound composition on the expression of fibrosis pathway-related proteins in adenine-induced mouse kidney

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織,並以西方墨點法進行分析分析Smad訊息傳遞路徑下游之促上皮間質轉化(epithelial mesenchymal transition,EMT)路徑蛋白表現。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for 10 weeks. At the end of the experiment, the mouse kidney tissues were taken and analyzed by Western blotting method to analyze the pathogenic protein expression of the epithelial mesenchymal transition (EMT) downstream of the Smad message transmission pathway.

由圖12及圖13結果顯示,誘導組相較於控制組,其中α-SMA和FN蛋白表現顯著增加,分別增加29.62、27倍。adenine 0.2%+AV 1%+PK 1%試驗組或adenine 0.2%+AV 2%+PK 1%試驗組與誘導組相比,可以顯著減少α-SMA蛋白表現,分別減少為誘導組的0.5、0.27倍,於adenine 0.2%+AV 2%試驗組或adenine 0.2%+PK 1%試驗組,有減少α-SMA蛋白表現的趨勢。於FN蛋白表現,誘導組與控制組相比顯著增加27.07倍,而adenine 0.2%+AV 1%+PK 1%試驗組、adenine 0.2%+AV 2%+PK 1%試驗組以及adenine 0.2%+PK 1%試驗組,可以顯著降低FN蛋白表現,分別降低為誘導組的0.6、0.56、0.42倍,於adenine 0.2%+AV 2%試驗組,FN蛋白表現雖有降低趨勢。因此,蘆薈豬腎複方組成物可顯著降低α-SMA和FN蛋白表現且具有相乘效果。The results of Fig. 12 and Fig. 13 show that the induction group showed a significant increase in α-SMA and FN protein compared with the control group, which increased by 29.62 and 27 times, respectively. Adenine 0.2%+AV 1%+PK 1% test group or adenine 0.2%+AV 2%+PK 1% test group can significantly reduce α-SMA protein performance compared with the induction group, respectively, reduced to 0.5 in the induction group. 0.27 times, in the adenine 0.2%+AV 2% test group or the adenine 0.2%+PK 1% test group, there was a tendency to reduce the expression of α-SMA protein. In the FN protein, the induction group was significantly increased by 27.07 times compared with the control group, while the adenine 0.2%+AV 1%+PK 1% test group, adenine 0.2%+AV 2%+PK 1% test group, and adenine 0.2%+ In the PK 1% test group, the FN protein expression was significantly reduced to 0.6, 0.56, and 0.42 times in the induction group, respectively. In the adenine 0.2%+AV 2% test group, the FN protein performance decreased. Therefore, the aloe porcine kidney compound composition can significantly reduce the expression of α-SMA and FN protein and have a multiplication effect.

接著分析EMT過程轉換增加的肌纖維母細胞,其對於腎臟間質區之促細胞外基質(extracellular matrix,ECM)累積的相關蛋白表現。由圖14及圖15結果顯示,誘導組與控制組相比較,會增加促細胞外基質蛋白PAI-1、C-1以及CTGF蛋白表現量,分別增加24.83、40.25、16.38倍。於adenine 0.2%+AV 1%+PK 1%試驗組與誘導組相比較,可以顯著減少PAI-1和C-1蛋白表現量,分別減少為誘導組的0.62、0.56倍,而CTGF雖有下降的趨勢,但未達統計上差異。高劑量AV合併PK試驗組和誘導組相比較,於adenine 0.2%+AV 2%+PK 1%試驗組分別可以顯著減少PAI-1、C-1以及CTGF蛋白表現量,分別減少為誘導組的0.49、0.15、0.24倍。而adenine 0.2%+AV 2%試驗組於C-1蛋白表現顯著減少為誘導組的0.43倍,adenine 0.2%+PK 1%試驗組於C-1蛋白表現減少為誘導組的0.7倍具減少的趨勢。因此,蘆薈豬腎複方組成物可顯著降低PAI-1、C-1以及CTGF蛋白表現量。The EMT process is then analyzed to convert the increased myofibroblasts, which are associated with the accumulation of proteins involved in the extracellular matrix (ECM) of the renal interstitial region. The results of Fig. 14 and Fig. 15 showed that the induction group increased the expression of the extracellular matrix proteins PAI-1, C-1 and CTGF, which were increased by 24.83, 40.25 and 16.38 times, respectively. Compared with the induction group, the adenine 0.2%+AV 1%+PK 1% test group can significantly reduce the PAI-1 and C-1 protein expression, which is reduced to 0.62 and 0.56 times of the induction group, respectively, while CTGF decreases. The trend, but not statistically different. Compared with the induction group, the high-dose AV combined with PK test group and the induced group can significantly reduce the PAI-1, C-1 and CTGF protein expression in the adenine 0.2%+AV 2%+PK 1% test group, respectively, and reduced to the induction group. 0.49, 0.15, 0.24 times. In the adenine 0.2%+AV 2% test group, the C-1 protein expression was significantly reduced to 0.43 times in the induction group, and the adenine 0.2%+PK 1% test group showed a decrease in C-1 protein expression to 0.7 times in the induction group. trend. Therefore, the aloe porcine kidney compound composition can significantly reduce the expression of PAI-1, C-1 and CTGF protein.

實施例9 蘆薈豬腎複方組成物對於腺嘌呤誘發小鼠腎臟中發炎路徑相關蛋白表現之影響Example 9 Effect of aloe porcine kidney compound composition on the expression of inflammation-related proteins in the kidney of mice induced by adenine

組別同實施例1,除了控制組以外,每天皆餵食0.2% (w/w)腺嘌呤誘導4週後,將AV及/或PK依劑量不同分別拌於標準飼料中合併治療6週。實驗共為期10週,在實驗結束後取小鼠腎臟組織,並以西方墨點法進行分析發炎相關蛋白之結果。The group was the same as in Example 1, except that the control group was fed with 0.2% (w/w) adenine every day for 4 weeks, and AV and/or PK were separately mixed in standard feed for 6 weeks. The experiment was carried out for a total of 10 weeks. At the end of the experiment, the kidney tissue of the mice was taken and the results of the inflammation-related proteins were analyzed by Western blotting.

由圖16及圖17結果顯示,發炎相關蛋白COX-2、NF-κB與iNOS的蛋白表現,誘導組與控制組相比較,分別上升7.56、4.34與4.49倍,皆達到統計上顯著差異。於試驗組方面,adenine 0.2%+AV 1%+PK 1%試驗組與誘導組相比較,NF-κB與iNOS的蛋白表現分別增加1.41、1.28倍,其中NF-κB之增加達到顯著差異。而adenine 0.2%+AV 2%+PK 1%試驗組與誘導組相比較,則可以顯著減少促發炎因子COX-2、NF-κB與iNOS的蛋白表現,分別減少為誘導組的0.5、0.74、0.2倍,達統計上顯著差異。於adenine 0.2%+AV 2%試驗組與誘導組相比較,在iNOS蛋白表現,可以顯著降低為誘導組的0.38倍,於COX-2與NF-κB蛋白表現,則無統計上差異。adenine 0.2%+PK 1%試驗組與誘導組相比較,在COX-2蛋白表現發現有顯著增加,增加1.05倍,於NF-κB和iNOS雖有增加的趨勢,但未達統計上顯著差異。因此,蘆薈豬腎複方組成物可顯著降低COX-2、NF-κB與iNOS蛋白表現量且具有相乘效果。The results of Fig. 16 and Fig. 17 showed that the protein expressions of the inflammatory related proteins COX-2, NF-κB and iNOS were increased by 7.56, 4.34 and 4.49 times, respectively, compared with the control group, which reached statistically significant differences. In the experimental group, the protein expression of NF-κB and iNOS increased by 1.41 and 1.28 times, respectively, in the adenine 0.2%+AV 1%+PK 1% test group compared with the induction group, and the increase of NF-κB was significantly different. Compared with the induction group, the adenine 0.2%+AV 2%+PK 1% test group can significantly reduce the protein expression of proinflammatory cytokines COX-2, NF-κB and iNOS, which are reduced to 0.5 and 0.74 in the induction group, respectively. 0.2 times, a statistically significant difference. Compared with the induction group, the expression of iNOS protein in adenine 0.2%+AV 2% test group was significantly reduced to 0.38 times that of the induction group. There was no statistical difference in COX-2 and NF-κB protein expression. Compared with the induction group, the adenine 0.2%+PK 1% test group showed a significant increase in COX-2 protein expression, an increase of 1.05 times. Although there was an increasing trend in NF-κB and iNOS, it did not reach statistically significant difference. Therefore, the aloe porcine kidney compound composition can significantly reduce the expression of COX-2, NF-κB and iNOS protein and have a multiplication effect.

根據本發明可作之不同修正及變化對於熟悉該項技術者而言均顯然不會偏離本發明的範圍與精神。雖然本發明已敘述特定的較佳具體事實,必須瞭解的是本發明不應被不當地限制於該等特定具體事實上。事實上,在實施本發明之已述模式方面,對於熟習該項技術者而言顯而易知之不同修正亦被涵蓋於下列申請專利範圍之內。It is apparent to those skilled in the art that various modifications and variations can be made without departing from the scope and spirit of the invention. Although the present invention has been described in terms of specific preferred embodiments, it should be understood that the invention should not be In fact, the various modifications that are apparent to those skilled in the art are also contemplated by the scope of the invention.

no

圖1為本發明之各組實驗動物之體重之折線圖;adenine為腺嘌呤;AV為蘆薈萃取物乾燥粉末之縮寫、PK為豬腎粉末之縮寫,詳細請參閱製備例1,以下圖2至圖17皆有相同之縮寫。 圖2為本發明之各組實驗動物之腎臟外觀照片與腎臟切片染色照片;最上排為小鼠犧牲當下所拍攝的腎臟影像;第二排為纖維化染色(Masson's trichrome stain),使用倍率為100倍;第三排為蘇木素-伊紅染色(hematoxylin and eosin stain,H&E stain),使用倍率為100倍。 圖3為本發明之各組實驗動物之腎臟重量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。 圖4為本發明之各組實驗動物腎臟組織之TGF-β1之蛋白質電泳圖;GAPDH (glyceraldehyde-3-phosphate dehydrogenase)為甘油醛-3-磷酸脫氫酶。 圖5為本發明之各組實驗動物腎臟組織之TGF-β1蛋白質表現量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。 圖6為本發明之各組實驗動物腎臟組織之p-Smad 2與Smad 2蛋白質電泳圖。 圖7為本發明之各組實驗動物腎臟組織之p-Smad 2/Smad 2蛋白質表現量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較;** P<0.01為與誘導組相比較。 圖8為本發明之各組實驗動物腎臟組織之p-Smad 3與Smad 3蛋白質電泳圖。 圖9為本發明之各組實驗動物腎臟組織之p-Smad 3/Smad 3蛋白質表現量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。 圖10為本發明之各組實驗動物腎臟組織之Smad 4蛋白質電泳圖。 圖11為本發明之各組實驗動物腎臟組織之Smad 4蛋白質表現量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較。 圖12為本發明之各組實驗動物腎臟組織之α-SMA與FN蛋白質電泳圖。 圖13為本發明之各組實驗動物腎臟組織之α-SMA與FN蛋白質表現量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。 圖14為本發明之各組實驗動物腎臟組織之PAI-1、C-1與CTGF蛋白質電泳圖。 圖15為本發明之各組實驗動物腎臟組織之PAI-1、C-1及CTGF蛋白質表現量之長條圖;統計為平均值±標準差;## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。 圖16為本發明之各組實驗動物腎臟組織之COX-2、NF-κB與iNOS蛋白質電泳圖。 圖17為本發明之各組實驗動物腎臟組織之COX-2、NF-κB及iNOS蛋白質表現量之長條圖;統計為平均值±標準差;# p<0.05、## p<0.01為與控制組相比較;* P<0.05、** P<0.01為與誘導組相比較。Figure 1 is a line drawing of the body weight of each group of experimental animals of the present invention; adenine is adenine; AV is an abbreviation of dry powder of aloe extract, and PK is an abbreviation of pig kidney powder. For details, please refer to Preparation Example 1, and Figure 2 below. Figure 17 has the same abbreviations. 2 is a photograph of the kidney appearance and kidney section of each group of experimental animals of the present invention; the top row is the kidney image taken by the mouse at the time of sacrifice; the second row is the Masson's trichrome stain, and the magnification is 100. The third row is hematoxylin and eosin stain (H&E stain), and the magnification is 100 times. Figure 3 is a bar graph of the kidney weight of each group of experimental animals of the present invention; the statistics are mean ± standard deviation; ## p < 0.01 is compared with the control group; * P < 0.05, ** P < 0.01 is The induction group was compared. 4 is a protein electrophoresis pattern of TGF-β1 in kidney tissues of experimental animals of the present invention; GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is glyceraldehyde-3-phosphate dehydrogenase. Figure 5 is a bar graph showing the expression of TGF-β1 protein in kidney tissues of experimental animals of the present invention; the mean is ± standard deviation; ## p < 0.01 is compared with the control group; * P < 0.05, * * P < 0.01 compared to the induction group. Figure 6 is a diagram showing the electrophoresis of p-Smad 2 and Smad 2 proteins in kidney tissues of experimental animals of the respective groups of the present invention. Each group of experimental animals renal tissue of the present invention in FIG. 7 p-Smad 2 / Smad 2 expression amount of a protein bar chart; counted as mean ± standard deviation; ## p <0.01 compared with the control group; ** P < 0.01 was compared with the induction group. Figure 8 is a diagram showing the electrophoresis of p-Smad 3 and Smad 3 proteins in kidney tissues of experimental animals of the respective groups of the present invention. Figure 9 is a bar graph showing the expression of p-Smad 3/Smad 3 protein in kidney tissues of experimental animals of the present invention; the mean is ± standard deviation; ## p < 0.01 is compared with the control group; * P <0.05, ** P<0.01 was compared with the induction group. Figure 10 is a diagram showing the Smad 4 protein electrophoresis of kidney tissue of each group of experimental animals of the present invention. Figure 11 is a bar graph showing the Smad 4 protein expression of kidney tissue of each group of experimental animals of the present invention; the statistics are mean ± standard deviation; ## p < 0.01 is compared with the control group. Figure 12 is a diagram showing the electrophoresis of α-SMA and FN proteins in kidney tissues of experimental animals of the respective groups of the present invention. Figure 13 is a bar graph showing the expression levels of α-SMA and FN protein in kidney tissues of experimental animals of the present invention; the statistics are mean ± standard deviation; ## p < 0.01 is compared with the control group; * P < 0.05 ** P < 0.01 was compared with the induction group. Figure 14 is a diagram showing the electrophoresis patterns of PAI-1, C-1 and CTGF proteins in kidney tissues of experimental animals of the respective groups of the present invention. Figure 15 is a bar graph showing the expression levels of PAI-1, C-1 and CTGF proteins in kidney tissues of experimental animals of the present invention; the statistics are mean ± standard deviation; ## p < 0.01 is compared with the control group; * P < 0.05, ** P < 0.01 compared to the induction group. Figure 16 is an electrophoresis pattern of COX-2, NF-κB and iNOS proteins in kidney tissues of experimental animals of the present invention. Figure 17 is a bar graph showing the expression levels of COX-2, NF-κB and iNOS proteins in kidney tissues of experimental animals of the present invention; the statistics are mean ± standard deviation; # p < 0.05, ## p < 0.01 The control group was compared; * P<0.05, ** P<0.01 was compared with the induction group.

no

Claims (9)

一種蘆薈豬腎複方組成物,其包含蘆薈萃取物乾燥粉末以及豬腎粉末;其中蘆薈萃取物乾燥粉末為脫色蘆薈凝膠以200:1濃縮後乾燥研磨成粉,豬腎粉末為乾燥後研磨成粉。The invention relates to aloe vera pig kidney compound composition, which comprises aloe vera extract dry powder and pig kidney powder; wherein the aloe extract dry powder is decolorized aloe vera gel, concentrated at 200:1, dried and ground into powder, and the pig kidney powder is dried and ground into powder. 如請求項1所述之蘆薈豬腎複方組成物,其中蘆薈萃取物乾燥粉末與豬腎粉末的重量比例介於1:1至2:1之間。The aloe porcine kidney compound composition according to claim 1, wherein the weight ratio of the aloe extract dry powder to the porcine kidney powder is between 1:1 and 2:1. 一種治療腎衰竭之醫藥品,其包含有效劑量之如請求項1或2所述之蘆薈豬腎複方組成物以及其藥學上可接受的載劑。A pharmaceutical preparation for treating renal failure comprising an effective amount of the aloe porcine kidney compound composition according to claim 1 or 2 and a pharmaceutically acceptable carrier thereof. 如請求項3所述之醫藥品,其中醫藥品為經腸道的或非經腸道的劑型。The pharmaceutical product according to claim 3, wherein the pharmaceutical product is an enteral or parenteral dosage form. 如請求項4所述之醫藥品,其中經腸道的劑型係口服劑型,其口服劑型係溶液、乳劑、懸浮液、粉末、錠劑、丸劑、口含錠、片劑、口嚼膠或膠囊。The pharmaceutical product according to claim 4, wherein the enteral dosage form is an oral dosage form, and the oral dosage form is a solution, an emulsion, a suspension, a powder, a lozenge, a pill, an ingot, a tablet, a chewing gum or a capsule. . 一種如請求項1或2所述之蘆薈豬腎複方組成物用於製造治療腎衰竭之醫藥品的用途,其中醫藥品含有有效劑量之蘆薈豬腎複方組成物以及其藥學上可接受的載劑。The use of the aloe porcine kidney compound composition according to claim 1 or 2 for the manufacture of a medicament for treating renal failure, wherein the medicament comprises an effective amount of aloe vera porcine kidney compound composition and a pharmaceutically acceptable carrier thereof . 如請求項6所述之用途,其中蘆薈豬腎複方組成物之人體有效劑量:蘆薈萃取物乾燥粉末介於每日每公斤0.13克(g/kg/day)至0.81 g/kg/day,豬腎粉末為0.13 g/kg/day至0.4 g/kg/day,且蘆薈萃取物乾燥粉末與豬腎粉末的重量比例介於1:1至2:1之間。The use according to claim 6, wherein the effective dose of the aloe vera compound composition: aloe extract dry powder is between 0.13 g/g/kg/kg/day/day, pig The kidney powder is from 0.13 g/kg/day to 0.4 g/kg/day, and the weight ratio of the aloe extract dry powder to the porcine kidney powder is between 1:1 and 2:1. 如請求項6所述之用途,其中腎衰竭,其形成途徑包含促進纖維化路徑因子p-Smad 3 (phosphorylated-mothers against decapentaplegic homolog 2) / Smad 3蛋白表現、抑制纖維化路徑因子p-Smad 2 / Smad 2蛋白表現、促進發炎因子、降低總抗氧化能力(trolox equivalent antioxidant capacity,TEAC)、降低抗氧化酵素的活性或其組合。The use of claim 6, wherein the renal dysfunction comprises a pathway that promotes the expression of a fibrotic-mothers against decapentaplegic homolog 2 / Smad 3 protein and inhibits the fibrogenic pathway factor p-Smad 2 / Smad 2 protein exhibits, promotes inflammatory factors, reduces total antioxidant capacity (TEAC), reduces antioxidant enzyme activity, or a combination thereof. 如請求項6至8中任一項所述之用途,其中腎衰竭的症狀包含腎纖維化。The use of any one of claims 6 to 8, wherein the symptom of renal failure comprises renal fibrosis.
TW106116586A 2017-05-19 2017-05-19 Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively TW201900203A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW106116586A TW201900203A (en) 2017-05-19 2017-05-19 Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW106116586A TW201900203A (en) 2017-05-19 2017-05-19 Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively

Publications (1)

Publication Number Publication Date
TW201900203A true TW201900203A (en) 2019-01-01

Family

ID=65803339

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106116586A TW201900203A (en) 2017-05-19 2017-05-19 Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively

Country Status (1)

Country Link
TW (1) TW201900203A (en)

Similar Documents

Publication Publication Date Title
KR101484587B1 (en) Composition effective for Alleviating Atopic Dermatitis Containing Mixture of Seamustard Sporophyll and Ascidian Tunic Extract
WO2022140841A1 (en) Transmucosal psychoactive alkaloid composition and preparation thereof
KR102218823B1 (en) Composition for anti-allergy comprising extract of lithospermum erythrorhizon
KR20170099539A (en) Sedum composition promoting antioxidant and alcohol oxidation
US20200188468A1 (en) A coated costus composition enriched with triterpenoids and a method of preparation of the same
JP2009013083A (en) Orally administerable composition
WO2021008265A1 (en) Anti-aging soft capsule for menopausal women and preparation method therefor
TW201900203A (en) Aloe/pig kidney composite composition and use of medicine used to treat kidney failure and produced thereby characterized by containing the aloe extract dried powder and the pig kidney powder to treat kidney failure effectively
WO2018209679A1 (en) Aloe-pig kidney compound composition and use thereof for manufacturing pharmaceuticals for treating kidney failure
WO2020248964A1 (en) Use of rhus chinensis fruit in preparation of drugs for treatment and/or prevention of hepatic fibrosis
US11096970B2 (en) Preparation and application of grain worm for treating diabetes
WO2021213230A1 (en) Application of traditional chinese medicine composition in preparation of drug for treating or preventing fatty liver disease
JP7228544B2 (en) A composition for preventing or treating nicotine addiction, comprising an extract of Liriope platyphylla as an active ingredient
US10105400B2 (en) Composition of chicken liver hydrolysates and method for improving alcohol metabolism, as well as preventing and treating liver fibrosis
TWI442920B (en) Usage of toona sinensis extract for preparing drugs for decreasing weight or body fat
JP3142192B2 (en) Blood lipid improving agent and composition containing the same
CN110420270A (en) A kind of functional composition containing camellia oil and fish oil and its application
Hussein et al. Comparing the effect of Moringa Oleifera aqueous leaves extract to insulin on submandibular salivary glands of Streptozotocin induced diabetic Albino rats (Histological and Immunohistochemical Study)
TWI815349B (en) Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes
KR101613252B1 (en) Compositions for Preventing or Treating Obesity and Fatty Liver Containing Ariginase Inhibitors
WO2019047141A1 (en) Pharmaceutical composition for controlling blood sugar
KR20170026242A (en) Pharmaceutical composition for treatment or prevention of liver disease
JP3183758B2 (en) Blood neutral fat ameliorating agent, method for producing the same, and composition containing the same
KR20170026241A (en) Complex preparation for oral use
WO2022113693A1 (en) Therapeutic agent for muscular dystrophy, central venous nutrition composition, inflammation inhibitor for muscle tissue, and anti-inflammatory food composition for muscular dystrophy